Table 1 Cohort of deliveries with and without medication exposure to repurposed medications.

From: A medication-wide association study (MWAS) on repurposed drugs for COVID-19 with Pre-pandemic prescription medication exposure and pregnancy outcomes

 

No medication exposure (N = 60,504)

Medication exposure (N = 2,830)

Total distinct deliveries (N = 63,334)

N

%

N

%

N

%

Pregnancy outcome

Cesarean section

19,856

32.82

1038

36.68

20,894

32.99

Preterm birth

3601

5.95

296

10.46

3897

6.15

Stillbirth

487

0.80

29

1.02

516

0.81

Comorbidities for adjustment

 

Adverse drug

27

0.04

*

0.32

36

0.06

Autoimmune

27

0.04

18

0.64

45

0.07

Cancer

312

0.52

85

3.00

397

0.63

Cardiovascular

411

0.68

202

7.14

613

0.97

Cerebrovascular

*

<0.01

*

0.11

*

0.01

Circulatory

18

0.03

29

1.02

47

0.07

Infectious disease

965

1.59

290

10.25

1255

1.98

Maternal care

214

0.35

50

1.77

264

0.42

Medication allergy

231

0.38

79

2.79

310

0.49

Multiple birth

1415

2.34

147

5.19

1562

2.47

Obesity

892

1.47

209

7.39

1101

1.74

Obstetric history

121

0.20

61

2.16

182

0.29

Organ transplant/acquired absence

20

0.03

18

0.64

38

0.06

Preeclampsia

4718

7.80

353

12.47

5071

8.01

Procedure

173

0.29

45

1.59

218

0.34

Respiratory

54

0.09

118

4.17

172

0.27

Toxic effect

*

 < 0.01

*

0.07

*

0.01

Mean maternal age +/− standard deviation

29.46 ± 6.07

29.67 ± 6.28

29.48 ± 6.08

  1. *Less than 10 patients.